MX2021006540A - Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). - Google Patents
Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19).Info
- Publication number
- MX2021006540A MX2021006540A MX2021006540A MX2021006540A MX2021006540A MX 2021006540 A MX2021006540 A MX 2021006540A MX 2021006540 A MX2021006540 A MX 2021006540A MX 2021006540 A MX2021006540 A MX 2021006540A MX 2021006540 A MX2021006540 A MX 2021006540A
- Authority
- MX
- Mexico
- Prior art keywords
- usp19
- inhibitors
- pharmaceutical compounds
- specific protease
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
Se proporcionan inhibidores de la USP19, métodos para tratar la obesidad, síndrome metabólico y/o diabetes usando los compuestos inhibidores de la USP19, así como aquellos compuestos para usarse en métodos para tratar la obesidad, el síndrome metabólico y/o la diabetes. También se proporcionan métodos para tratar la atrofia muscular, por ejemplo, caquexia o sarcopenia con compuestos inhibidores de la USP19, además de aquellos compuestos para usarse en métodos para tratar la atrofia muscular.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1819937.2A GB201819937D0 (en) | 2018-12-06 | 2018-12-06 | Pharmaceutical compounds |
GBGB1904339.7A GB201904339D0 (en) | 2019-03-28 | 2019-03-28 | Pharmaceutical compounds |
GBGB1911311.7A GB201911311D0 (en) | 2019-08-07 | 2019-08-07 | Pharmaceutical compounds |
PCT/GB2019/053457 WO2020115501A1 (en) | 2018-12-06 | 2019-12-06 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006540A true MX2021006540A (es) | 2021-07-07 |
Family
ID=68887435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006540A MX2021006540A (es) | 2018-12-06 | 2019-12-06 | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220033397A1 (es) |
EP (1) | EP3890829A1 (es) |
JP (1) | JP2022512128A (es) |
KR (1) | KR20210102285A (es) |
CN (1) | CN113365696A (es) |
AU (1) | AU2019393162A1 (es) |
BR (1) | BR112021010644A2 (es) |
CA (1) | CA3121376A1 (es) |
IL (1) | IL283706A (es) |
MX (1) | MX2021006540A (es) |
SG (1) | SG11202105913RA (es) |
WO (1) | WO2020115501A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
GB202104097D0 (en) | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
JP4459619B2 (ja) | 2001-10-02 | 2010-04-28 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物 |
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
TWI770525B (zh) * | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
MA41291A (fr) * | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
EP3253759A1 (en) * | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2016126926A1 (en) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
JP2018504431A (ja) * | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン |
UA123793C2 (uk) * | 2016-06-10 | 2021-06-02 | Ле Лаборатуар Сервьє | Нові (гетеро)арил-заміщені похідні піперидинілу, спосіб їхнього одержання та фармацевтичні композиції, що їх містять |
FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB201612938D0 (en) | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 CA CA3121376A patent/CA3121376A1/en active Pending
- 2019-12-06 EP EP19821176.5A patent/EP3890829A1/en active Pending
- 2019-12-06 WO PCT/GB2019/053457 patent/WO2020115501A1/en unknown
- 2019-12-06 JP JP2021532111A patent/JP2022512128A/ja active Pending
- 2019-12-06 BR BR112021010644-8A patent/BR112021010644A2/pt unknown
- 2019-12-06 SG SG11202105913RA patent/SG11202105913RA/en unknown
- 2019-12-06 CN CN201980090768.3A patent/CN113365696A/zh active Pending
- 2019-12-06 US US17/299,959 patent/US20220033397A1/en active Pending
- 2019-12-06 KR KR1020217020079A patent/KR20210102285A/ko active Search and Examination
- 2019-12-06 MX MX2021006540A patent/MX2021006540A/es unknown
- 2019-12-06 AU AU2019393162A patent/AU2019393162A1/en not_active Abandoned
-
2021
- 2021-06-03 IL IL283706A patent/IL283706A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021010644A2 (pt) | 2021-09-28 |
CA3121376A1 (en) | 2020-06-11 |
JP2022512128A (ja) | 2022-02-02 |
EP3890829A1 (en) | 2021-10-13 |
IL283706A (en) | 2021-07-29 |
KR20210102285A (ko) | 2021-08-19 |
AU2019393162A1 (en) | 2021-06-17 |
SG11202105913RA (en) | 2021-07-29 |
US20220033397A1 (en) | 2022-02-03 |
WO2020115501A1 (en) | 2020-06-11 |
CN113365696A (zh) | 2021-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018017368A9 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GUT OR HYPERURICEMIA | |
AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
EP3723775A4 (en) | MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME | |
MY191321A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
GEP20125511B (en) | Mapk/erk kinase inhibitors | |
MX2021003187A (es) | Inhibición de la peptidasa específica de ubiquitina 9x. | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
MX2022001004A (es) | Inhibidores de enzimas. | |
WO2020041169A3 (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
MX2021006540A (es) | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). | |
EA201890728A2 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
MX2020008091A (es) | Derivados de 4-hidroxipiperidina y su uso como inhibidores de proteasa especifica de ubiquitina 19 (usp19). | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
CA3035115C (en) | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | |
WO2020127259A3 (en) | Materials for electronic devices | |
MX2012001999A (es) | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. | |
MX2020005373A (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis. | |
MX2017009110A (es) | Terapia de combinacion para hipertension pulmonar. | |
IL281450A (en) | Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses thereof | |
MX2021006542A (es) | Inhibidores de la usp19 para usarse en terapia. | |
AU2017258649A1 (en) | Covalent BTK inhibitors and uses thereof |